Bank of Montreal Can Has $13.85 Million Stake in ANI Pharmaceuticals, Inc. $ANIP

Bank of Montreal Can lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 212,228 shares of the specialty pharmaceutical company’s stock after selling 3,493 shares during the period. Bank of Montreal Can’s holdings in ANI Pharmaceuticals were worth $13,848,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in ANI Pharmaceuticals by 68.3% during the 1st quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company’s stock worth $10,565,000 after acquiring an additional 64,021 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in ANI Pharmaceuticals by 31.0% in the first quarter. Envestnet Asset Management Inc. now owns 6,457 shares of the specialty pharmaceutical company’s stock worth $432,000 after purchasing an additional 1,527 shares during the period. Hohimer Wealth Management LLC boosted its position in shares of ANI Pharmaceuticals by 5.2% during the first quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company’s stock worth $334,000 after purchasing an additional 247 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of ANI Pharmaceuticals by 22.4% in the 1st quarter. Victory Capital Management Inc. now owns 16,863 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after buying an additional 3,086 shares during the period. Finally, Allianz Asset Management GmbH bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $415,000. 76.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO Stephen P. Carey sold 50,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $86.07, for a total transaction of $4,303,500.00. Following the transaction, the chief financial officer directly owned 180,863 shares in the company, valued at $15,566,878.41. The trade was a 21.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeanne Thoma sold 21,540 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $89.15, for a total transaction of $1,920,291.00. Following the completion of the sale, the director directly owned 23,405 shares in the company, valued at approximately $2,086,555.75. The trade was a 47.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 413,830 shares of company stock worth $36,505,378. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. JPMorgan Chase & Co. raised their price objective on ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. HC Wainwright raised their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Guggenheim lifted their price objective on ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a “buy” rating in a report on Monday, September 8th. Weiss Ratings raised ANI Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, October 24th. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $99.14.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $90.43 on Friday. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The business has a 50-day moving average of $93.58 and a 200-day moving average of $77.60. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -117.44 and a beta of 0.54. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. During the same period last year, the company earned $1.34 earnings per share. The business’s revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.